Business Context and Reporting Period
This Form 8-K Current Report was filed by 4D Molecular Therapeutics, Inc. (FDMT) on February 22, 2022, covering events occurring on February 17, 2022. The company is a Delaware corporation with principal executive offices in Emeryville, CA, and its common stock trades on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the departure of a director and officer:
- Resignation: David Schaffer, Ph.D., resigned from the Board of Directors, effective immediately on February 17, 2022.
- Committee Roles: Dr. Schaffer also resigned from his roles on the Nominating and Corporate Governance Committee and the Science & Technology Committee.
- Consulting Agreement: Dr. Schaffer notified the Company of his intention to terminate his consulting agreement.
- Reason for Departure: The resignation is not the result of any disagreement with the Company or the Board regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items beyond the director resignation.
Investor Verification Checklist
- Confirm the effective date of Dr. Schaffer's resignation and the status of his consulting agreement termination.
- Verify if the Board has initiated a search for a replacement director to fill the vacancy on the Science & Technology Committee.
- Review subsequent filings to determine if this departure impacts the company's strategic direction or scientific oversight.